ENCEFA is a biotechnology company developing novel CD38 modulators that clean up suffering cells (whole autophagy-lysosomal flux activation) and boost their energy metabolism, making them effective again in the context of age-related diseases.
ENCEFA leverages on the discovery of a new biological pathway that uses CD38 in an unprecedent manner (3 patents filed), by simply mimicking a key natural rescue mechanism every one of us physiologically have, but which is impaired with aging, while beside increasing NAD+ levels.
Stemming from the Pitié Salpêtrière Hospital, Paris, FRANCE, and incorporated in 2016, ENCEFA is on a mission to extend our Healthy Longevity.
Through this novel anti-aging mechanism, our products shown their ability to rejuvenate the key organs of our body and to calm down inflammation, under several pathological contexts in a preclinical setting (mice, rats, dogs).
Our most advanced product, NC-B8, is a first-in-class brain penetrant antibody, developed against neurodegenerative diseases, starting with Amyotrophic Lateral Sclerosis (ALS).
NC-P7, is our second product activating the same anti-aging mechanism of action, developed to protect the heart and the kidney in the context of age-related metabolic disorders.
Company Details
- Founded
- -
- Address
- 47 Boulevard De L'hôpital, Paris,75013,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.encefa.com
- HQ
- Paris
Encefa Questions
Encefa's website is http://www.encefa.com
Encefa's LinkedIn profile is https://fr.linkedin.com/company/encefa
Encefa's industry is
Biotechnology Research
Encefa's top competitors are
Asmodee,
Pegascy,
Orakl Oncology,
Onward Therapeutics,
Karcinolys,
Occlugel Sas.,
Pharmès,
Jalon Therapeutics,
Ennodc,
Amyl Therapeutics.
Encefa's categories are Biotechnology Research
Encefa's founding year is 2016
